Searching map area
Phase I study with pegylated human IL-10 (AM0010) alone or in combination with anti-PD-1 or FOLFOX-immune biomarker update.
? TBD
scholarly article
2017
Nobody has rated this yet. Be the first!
Lists 0
Abstract

157 Background: Persistence of activated CD8 T cells is essential for the durability of tumor immune responses. IL-10 is an anti-inflammatory cytokine, PEGylated IL-10 (AM0010) enhances tumor specific CD8 T cell expansion and cytotoxicity. We evaluated tolerability and efficacy of AM0010 alone, with chemotherapy or anti-PD-1 in a phase 1 study. AM0010 alone induces objective anti-tumor responses without auto-immune toxicities. AM0010 with anti-PD-1 was evaluated in RCC (n=8) or NSCLC (n=5)...

Authors Aung Naing, Jeffrey R. Infante, J. Randolph Hecht, Kyriakos P. Papadopoulos, Deborah Jean Lee Wong, Karen A. Autio, Gerald Steven Falchook, Manish R. Patel, Patrick Alexander Ott, Amita Patnaik
Volume Vol. 35, No. 7_suppl, pp. 157-157
Reading
Instance of
Published in
Subject
References